Pharmacovigilance program to monitor adverse reactions of recombinant streptokinase in acute myocardial infarction

BACKGROUND: Streptokinase (SK) is an effective fibrinolytic agent for the treatment of acute myocardial infarction (AMI). The objective of the present study was to assess the adverse drug reactions (ADRs) associated with intravenous recombinant SK in patients with AMI in routine clinical practice. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Betancourt, Blas Y, Marrero-Miragaya, María A, Jiménez-López, Giset, Valenzuela-Silva, Carmen, García-Iglesias, Elizeth, Hernández-Bernal, Francisco, Debesa-García, Francisco, González-López, Tania, Alvarez-Falcón, Leovaldo, López-Saura, Pedro A
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2005
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1291362/
https://www.ncbi.nlm.nih.gov/pubmed/16262910
http://dx.doi.org/10.1186/1472-6904-5-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1291362/
https://www.ncbi.nlm.nih.gov/pubmed/16262910
http://dx.doi.org/10.1186/1472-6904-5-5

Ejemplares similares